Market Overview

UPDATE: Jefferies Reiterates on Actavis PLC Following In-Line Q3 Results, Solid '14 Guidance

Morgan Stanley: We Still Like Actavis Despite Weaknesses
And The Winner From The Mylan-Perrigo Merger Is... Teva?
Global Worries Sink U.S. Stocks; Apple Breaches Support Level (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Oren G. Livnat reiterated a Hold rating on Actavis PLC (NYSE: ACT), and raised the price target from $133.00 to $168.00.

In the report, Jefferies noted, “ACT delivered in-line Q3 and solid 1st-time ‘14 guide w/ WCRX that looks conservative. ACT renewed a promise of ‘double-digit' organic growth off the higher earnings base; impressive w/ WCRX's lower growth. Mgmt likely has the levers at its disposal to make it happen and we raise '15-'16. Yet, with ambiguity around Gx pipeline and lifecycle risk on important WCRX franchises, it's hard to justify a premium branded multiple here. Raise to $168. Maintain Hold.”

Actavis PLC closed on Tuesday at $154.27.

Latest Ratings for ACT

Apr 2015BarclaysMaintainsEqual-weight
Apr 2015Leerink SwannMaintainsOutperform
Mar 2015Sterne AgeeMaintainsBuy

View More Analyst Ratings for ACT
View the Latest Analyst Ratings

Posted-In: Jefferies Oren G. LivnatAnalyst Color Price Target Analyst Ratings


Related Articles (ACT)

Around the Web, We're Loving...

Get Benzinga's Newsletters